anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject particle having an enlarged specific surface area, capable of exhibiting a high effect as a microorganism flocculating agent by bonding an organic group containing a pyridinium base to a fine inorganic particle. SOLUTION: This inorganic particle comprises an organic group containing pyridinium base on the surface. The inorganic particle is preferably selected from a metal, a metal oxide, a metal nitride, a metal carbide and a metal sulfide and the diameter of the inorganic particle is preferably <=5 μm, preferably <=1 μm. The organic group is preferably a polymer. The bonding of the organic group containing the pyridinium base to the inorganic particle can be carried out by formulating an organic group precursor containing the pyridinium base with the inorganic particle in a proper solvent or by a reaction such as hydrolysis or condensation. Preferably, a substance having selective bondability (preferably an antigen or an antibody) is bonded to the surface of the inorganic particle.
The invention relates to a personal data network having a server device for storing personal data of a user, and having a computer unit associated with a user. The computer unit and the server device communicate via a network in order to exchange de-personalized data. The personal data network arises from the fact that only data which permit no direct or indirect conclusions to be drawn about the person is conducted via the network and stored in the network. Of The personal data of the user is already de-personalized on the computer unit by an identifier and is transmitted to the server device, where it is stored in a de-personalized manner under the identifier. The identifier results from an allocation rule stored only on the computer unit. Personalization of the de-personalized personal data in the form of an allocation of the de-personalized personal data to the associated user is not possible
Different studies and systematic reviews have reported weight increase after tonsillectomy. However, the odds of a child being overweight or obese after tonsillectomy were no different than before surgery, according to a few studies. This systematic review aims to analyze the impact of adenotonsillectomy (TA) on weight gain and identify subgroups of children and adolescents at risk of experiencing weight gain. A systematic search included studies published in the last ten years. The PICO framework was used in the selection process, and evidence was assessed using the GRADE system. A total of 26 studies were included, and moderate-high level quality ones showed that children who underwent TA could present an increase in BMI z-score. However, this weight gain was significant in individuals younger than six years old and was considered catch-up growth in underweight subjects at baseline. In contrast, for normal-weight or overweight individuals, TA did not lead to overweight per se. At the same time, diet changes and overfeeding did not have a leading role in weight gain. In conclusion, TA may not be an independent risk factor for unfavorable weight gain in children; however, individuals who were underweight pre-operatively or younger than six years reported more weight gain after TA than expected.
The present invention discloses a Chinese medicine preparation for drug abstinence, which comprises the components of the following weight part proportion: 7 to 15 parts of ginseng, 3 to 8 parts of aconite root, 5 to 10 parts of raw licorice root, 4 to 9 parts of white atractylodes rhizome, 7 to 14 parts of Indian bread, 3 to 8 parts of sharpleaf galangal fruit, 3 to 8 parts of ginger slice, 5 to 15 parts of corydalis tuber, 1 to 5 parts of upright datura flower, 3 to 8 parts of amur corktree bark, 3 to 8 parts of kusnezoff monkshood root, 7 to 14 parts of wild jujube seed, 10 to 30 parts of orientvine stem and 4 to 8 parts of stone-like omphalia. The present invention mainly strengthens body's resistance and stabilizes addiction abstinence. Since medicine sources are rich and preparation is simple, the present invention is low in cost and has no toxic or side effect. The present invention is capable of stopping the drug addiction of bodies, controlling mind addiction, expelling toxin, tranquilizing mind and alleviating pain, and has the advantages of fast medicine effect, no addiction, stable therapeutic effect and no toxic or side effect. Drug abstainers can finish drug abstinence under the condition of no pain, and household drug abstinence is convenient. Thus, the present invention is a novel and unique Chinese medicine preparation for drug abstinence.
BACKGROUND: Cupriavidus gilardii is an aerobic, gram-negative, motile, glucose-nonfermenting bacillus, first described in 1999. Typically, it exhibits low pathogenicity in humans, causing opportunistic infections primarily in individuals with compromised immune systems. This bacterium has been also found in various environmental sources such as plants and contaminated soils. Notably, there have been no documented cases of C. gilardii infections in animals.
CASE PRESENTATION: This case report outlines a bovine neonatal diarrhea outbreak that occurred in Northern Greece, during which C. gilardii was isolated. Faecal samples from 5-day-old calves were collected and transported to the laboratory for further examination. Bacterial culture and next generation sequencing techniques were employed to confirm the presence of this bacterium in the samples. Following the isolation and identification of C. gilardii from the samples, an autogenous vaccine was produced and administered to the cows within the farm. Subsequent to vaccination, a progressive reduction in calf diarrhea and deaths was observed, leading to their eventual complete resolution. To the best of our knowledge, this represents the first documentation of C. gilardii isolation from cases of bovine neonatal diarrhea.
CONCLUSION: This case report presents the first isolation case of C. gilardii from animal samples and more specifically from calf faecal samples. It represents an important observation, providing evidence that this opportunistic human pathogen could contribute to clinical symptoms in animals.
Bacillus cereus is a pathogenic bacterium that causes food contamination, resulting in food poisoning such as diarrhea and emesis. Therefore, it is crucial to develop effective strategies to control this bacterium. In this study, we isolated and characterized a novel B. cereus phage, named DZ1. Morphological and genomic analyses revealed that phage DZ1 is a new species belonging to the Andromedavirus genus. Phage DZ1 was tolerant to a wide range of pH values (5-9), temperatures (4-55 ℃), and high concentrations of NaCl solution (1000 mM). B. cereus with 21 different sequence types (STs) can be lysed by phage DZ1. Importantly, phage DZ1 inhibited B. cereus growth in spiked rice substrates or milk up to 36 and 72 h, respectively, with suppression of 3 log. Therefore, phage DZ1 is a useful biocontrol agent for the control of B. cereus in the food industry.
After positioning a silicon belt for Electrical Impedance Tomography (EIT) and a baseline record, patients will receive the treatment of High Frequency Percussive Ventilation. Further recordings will be acquired soon after the end of the treatment, 1 and 3 hours later.
In the enrollment, women whose cervical histopathological results have been diagnosed as low-grade squamous intraepithelial lesion (LSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
Chronic use of opiates is a rapidly escalating crisis in the United States, with over 4.3 million Americans dependent on opiate analgesic, an escalating rate of opiate overdose deaths, and a resurgence of intravenous heroin use leading to total societal cost exceeding $55 billion. The struggle to break the addiction cycle is likely due to factors that affect neural circuits that govern craving and cognitive control. There is growing interest in the utilization of prefrontal cortex repetitive transcranial magnetic stimulation (rTMS) as a novel, non-invasive, non-pharmacologic approach to decreasing craving among chronic opiate users. At this early stage of development, however, it is unclear if the best TMS strategy is to (Strategy 1, Aim 1) increase activity in the dorsolateral prefrontal cortex, or (Strategy 2, Aim 2) decrease activity in the ventromedial prefrontal cortex.

DESIGN: To parametrically evaluate these two promising treatment strategies, the investigators have developed a design where opiate dependent individuals and healthy controls will be randomized to receive either one placebo-like TMS treatment, or one of two real TMS treatments (DLPFC iTBS or MPFC cTBS). Participants with opiate dependence will be recruited from the local community, as well as the MUSC Center for Drug and Alcohol Programs (CDAP), the Ralph H. Johnson Substance Abuse Treatment Center and local pain clinics. Healthy controls will be recruited from the local community. Approved Study Team Members will visit the above mentioned clinics and community and talk with patients. Individuals who consent will receive interleaved TMS/BOLD imaging and our established MRI-based thermal pain paradigm immediately before and after rTMS. The investigators will also measure subjective pain and opiate craving ratings. The relative efficacy of Strategy 1 vs 2 will directly translate to development of a large clinical trial of rTMS as an innovative, new treatment option for pain in opiate dependent individuals.
INTRODUCTION: Established personal and familial risk factors contribute collectively to a woman's risk of breast or ovarian cancer. Existing clinical services offer genetic testing for pathogenic variants in high-risk genes to investigate these risks but recent information on the role of common genomic variants, in the form of a Polygenic Risk Score (PRS), has provided the potential to further personalise breast and ovarian cancer risk assessment. Data from cohort studies support the potential of an integrated risk assessment to improve targeted risk management but experience of this approach in clinical practice is limited.
METHODS AND ANALYSIS: The polygenic risk modification trial is an Australian multicentre prospective randomised controlled trial of integrated risk assessment including personal and family risk factors with inclusion of breast and ovarian PRS vs standard care. The study will enrol women, unaffected by cancer, undergoing predictive testing at a familial cancer clinic for a pathogenic variant in a known breast cancer (BC) or ovarian cancer (OC) predisposition gene (BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51C, RAD51D). Array-based genotyping will be used to generate breast cancer (313 SNP) and ovarian cancer (36 SNP) PRS. A suite of materials has been developed for the trial including an online portal for patient consent and questionnaires, and a clinician education programme to train healthcare providers in the use of integrated risk assessment. Long-term follow-up will evaluate differences in the assessed risk and management advice, patient risk management intentions and adherence, patient-reported experience and outcomes, and the health service implications of personalised risk assessment.
ETHICS AND DISSEMINATION: This study has been approved by the Human Research Ethics Committee of Peter MacCallum Cancer Centre and at all participating centres. Study findings will be disseminated via peer-reviewed publications and conference presentations, and directly to participants.
TRIAL REGISTRATION NUMBER: ACTRN12621000009819.
The present invention relates to compositions comprising an inhibitor of a polynucleotide, said polynucleotide to be inhibited being capable of decreasing or suppressing expression of FZD3 (Frizzled-3) or a biologically active derivative thereof for use in treating or preventing bone disorders and/or cardiovascular disorders. Such bone disorders comprise,  inter alia , osteoporosis, osteopenia, bone fracture, bone cancer, as well as impaired bone homeostasis. Cardiovascular diseases to be treated by the compounds of the present invention may be selected from the group consisting of infarction, stroke, hypertension, thrombosis, vascular stenosis, coronary syndromes, vascular dementia, heart failure, renal failure, stress-related cardiovascular disorders and atherosclerosis. Preferred compounds to be used in these medical interventions are antagonistic compounds, like nucleic acid molecules, directed against miR- 31 and derivatives thereof. Also, the present invention relates to methods for diagnosing and compositions for use in diagnosing bone disorders and/or cardiovascular disorders. Compounds to be employed in these diagnostic methods and uses may be compounds (like primers and probes) that are capable of detecting such a polynucleotide that is capable of decreasing or suppressing expression of FZD3 or a biologically active derivative thereof. miR-31 is provided herein as a polynucleotide that is capable of decreasing or suppressing expression of FZD3.
BACKGROUND: Bladder cancer (BC) is a prevalent malignancy characterized by significant cellular heterogeneity. While single-cell multi-omics studies have provided valuable insights, much of the existing data remains underexplored, limiting our understanding of BC's molecular mechanisms. Uncovering the pathogenesis of BC and finding new treatment methods are urgent problems to be solved. This study aims to address this gap by re-analyzing available single-cell datasets to uncover novel insights into BC.
METHODS: In this study, we retrieved three single-cell transcriptome datasets by searching the Gene Expression Omnibus (GEO) database, focusing on single-cell sequencing of normal mouse bladder within the past 5 years. Through quality control and batch effect elimination, we obtained a total of 24,930 cells including epithelial, stromal, and immune cells. Subgroup analysis, pseudotemporal analysis, cell-cell communication, and transcription factor analysis were conducted specifically on epithelial cells to identify a transitional state during basal cell differentiation. We further compared the expression profiles of key transcription factors in cancer and normal tissues. In addition, we also performed immunohistochemical staining and survival analysis for key transcription factors.
RESULTS: Subgroup analysis revealed multiple subtypes of epithelial cells, including basal, umbrella, and intermediate cells. Through pseudotemporal analysis, we discovered the developmental trajectory from basal cells to umbrella cells and further found that Basal_I is a transitional state for basal cell differentiation. Cell-to-cell communication analyses highlighted the pivotal role of Basal_I in cell-cell interactions, and key ligand-receptor pairs associated with cancer progression were also identified. Furthermore, elevated expression levels of key transcription factors in Basal_I were found to be closely associated with the stage and prognosis of BC. Immunohistochemical staining results further confirmed the upregulated expression of these transcription factors in BC.
CONCLUSIONS: Collectively, we found a transitional state of basal cells in normal bladder epithelial cells in mice, which may be related to the occurrence and development of BC, providing important clues for further understanding of the pathogenesis of BC. Our study provided possible molecular mechanisms or target for the research and treatment of BC.
OBJECTIVE: To analyze the effects of using foam roller on pain intensity in individuals with chronic and acute musculoskeletal pain.
METHODS: This systematic review was registered in the National Institute for Health Research's prospective online registry of systematic reviews (PROSPERO) under CRD42023456841. The databases Pubmed, Medline (via Ovid), Embase, BVS, and PEDro (Physiotherapy Evidence Database) were consulted to carry out this systematic review. Notably, the records of clinical trials characterized as eligible were manually searched. The search terms were: (foam rolling OR foam rolling vibration) AND (acute musculoskeletal pain) AND (chronic musculoskeletal pain). The search was performed until August 22, 2023. For the analysis of the methodological quality, the PEDro scale was used for each of the manuscripts included in the systematic review. Due to the heterogeneity in the studies included in this systematic review, performing a meta-analysis of the analyzed variables was impossible.
RESULTS: Only six manuscripts were eligible for data analysis. The type of FR used was non-vibrational, being applied by a therapist in only one of the manuscripts. With an application time ranging from at least 45 s to 15 min, the non-vibrational FR was applied within a day up to six weeks. Using the PEDro scale, scores were assigned that varied between 4 and 8 points, with an average of 6 ± 1.29 points. Only two randomized clinical trials found a significant benefit in pain intensity of adding FR associated with a therapeutic exercise protocol in individuals with patellofemoral pain syndrome and chronic neck pain.
CONCLUSION: The results of this systematic review do not elucidate or reinforce the clinical use of FR in pain intensity in individuals with chronic and acute musculoskeletal pain.
Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
PROBLEM TO BE SOLVED: To obtain an antioxidant, having excellent antioxidant actions and high safety and utilizable as medicine, cosmetics, food additives, etc., by including an extract essence of a fruit of Phellodendron amurense as an active ingredient therein. SOLUTION: This antioxidant comprises an extract essence obtained by extracting a fruit of Phellodendron amurense with a solvent such as water or methanol as an active ingredient. For example, 500ml water is added to 50g fruit of the Phellondendron amurense and the resultant mixture is then heated at 100 deg.C for 30min to carry out extraction twice. The resultant extract solutions can be combined and freeze-dried to afford 16 g aqueous extract essence. Furthermore, 50g fruit of the Phellodendron amurense is heated with 500ml methanol at 50 deg.C for 30min and extracted with methanol twice and the resultant extract solutions are combined and vacuum concentrated to provide 10g methanol extract essence. Thereby, the antioxidant can suitably be used for foods, medicines, etc., in combination with few kinds of well-known antioxidants derived from a natural product such as ascorbic acid.
This study is a single center and open-label design to evaluate tolerability, safety and pharmacokinetic properties of HUYPS-1 after single oral administration in healthy subjects under fasting conditions. A total of 14 eligible subjects are expected to be enrolled to ensure 12 evaluable subjects. The study will be completed when there are at least 12 evaluable subjects. The evaluable subjects are those who have completed both periods. Eligible subjects will be randomly assigned to either of the two treatment sequences.

The study design in a 2-sequence, 2-period crossover design. There is at least 7-day washout time between periods. The formulation of HUYPS-1 for oral administration contains 100 mg mannitol and 100 mg sucralose per tablet will be given by one or nine tablets per person of each period. Mannitol and sucralose are both commonly used excipients approved by WHO. These excipients are included in the FDA Inactive Ingredients Guide, GRAS (generally recognized as safe) and commonly used pharmaceutical excipients, therefore the oral doses of these excipients can be regarded as extremely safe in this study.
1,213,081. Hydraulic motor control circuits. CATERPILLAR TRACTOR CO. Feb. 28, 1969 [March 6, 1968], No. 10853/69. Heading F1P. The detent-held manual control 24 of a cylinder and piston motor 11 is tripped by a control plunger 34 in cylinder 33 by the displacement of a volume of the hydraulic fluid. As shown fluid is trapped between the rod 21 and plunger 36 when the piston moves to the right and, after fitting accumulator 41 of variable effective capacity, extends 34 to free the spring centred spool valve 12 and allow it to close. The effective stroke of the motor is altered by screw 43 of accumulator 41. On manual override excess control pressure is vented at 47 and the consequent partial vacuum or reverse stroke is relieved by 48, 41, 47 and 48 may be incorporated in the cylinder, Fig.3 (not shown). In Fig.2 (not shown) the control plunger arrangement is modified so as to cause the control to be effective as the piston moves to the left. In a further embodiment, Fig.4 (not shown) an enlargement (72) on the piston rod enters a restricted diameter portion (71) of the cylinder to generate the control prisms.
OBJECTIVES: This study looked at the role of anti-carbamylated protein (anti-CarP) antibodies in contributing to lung fibrosis in CTD-associated interstitial lung disease (ILD) in an autoantigen-dependent manner.
METHODS: ELISA was used to test serum samples, including 89 from the CTD-ILD group and 170 from the non-CTD-ILD group, for anti-CarP levels. Male C57BL/6 mice were used for the pulmonary fibrosis model and anti-CarP treatment in vivo (n = 5) and patient serum-derived or commercialized anti-CarP was used for cell treatment. We identified the carbamylated membrane protein via immunofluorescence (IF) and co-immunoprecipitation followed by mass spectrometry (MS) analysis. Quantitative RT-PCR, IF and western blot were performed to explore the antigen-dependent role of anti-CarP. A native electrophoretic mobility shift assay and MS analysis were used to verify direct interaction and carbamylation sites.
RESULTS: A significantly higher serum anti-CarP level was observed in CTD with ILD than without ILD. In vivo, intrapulmonary delivery of anti-CarP induces epithelial-mesenchymal transition (EMT) and microfibrotic foci. Carbamylation was enriched in type II alveolar epithelial cells (AEC II). A novel carbamylated membrane receptor, specifically recognized by anti-CarP, was identified as toll-like receptor 5 (TLR5). We found anti-CarP induces the nuclear translocation of NF-κB and downstream events, including EMT and expression of inflammatory cytokines in AEC II, which were reversed by TLR5 blocking or TLR5 knockdown. Moreover, up to 12 lysine carbamylation sites were found in TLR5 ectodomain, allowing the interaction of anti-CarP with carbamylated TLR5.
CONCLUSIONS: Overall, we found anti-CarP drives aberrant AEC II activation by interacting with carbamylated TLR5 to promote ILD progression.
PROBLEM TO BE SOLVED: To provide a liquid nutritive composition containing proteins, carbohydrates, and oils and fats in a good balance to give freshness by sour taste and visually fresh transparency, and, further, to provide the liquid nutritive composition having a low viscosity to give freshness with easiness in drinking, free from an odor or a bitter taste, and having a low osmotic pressure and high emulsion stability.SOLUTION: An oral liquid nutritive composition contains protein, carbohydrate, an emulsifying agent, oils and fats, and water. The protein (A) is compounded by 2 to 11 mass%, the carbohydrate (B) is compounded by 10 to 35 mass%, and the emulsifying agent (C) and the oils and fats (D) are compounded in total by 1 to 13 mass%. The protein (A) comprises collagen peptide and milk peptide having a decomposition degree of 23 to 35. The carbohydrate (B) comprises a decomposed product of starch having a number average molecular weight of 400 to 900. The emulsifying agent (C) comprises a polyglycerol fatty acid ester, which is an ester of polyglycerol having an average polymerization degree of 5 or more with either oleic acid or myristic acid. The oils and fats (D) contain MCT and have a pH of 3.0 to 5.0.